1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. UPSTREAM BIO INC.
Upstream Bio Inc.
XNAS: UPB
Download real time
9.31 -0.09 (-0.96%)
72.36% Fall from 52W High
300.4K
XNAS Volume

XNAS 04 May, 2026 5:30 PM (EDT)

Watchlist

Portfolio

Alert
Board Meeting
The next board meeting for Upstream Bio Inc is on 06 May 2026 for the purpose of Upstream Bio Inc First Quarter Earnings Results for 2026 See details


Insider Trading disclosures for Upstream Bio Inc

The latest disclosure was made by Allison Ambrose in Upstream Bio Inc where a trade of 475 Common Stock done at an average price of $9.3 was reported to US exchanges on March 16, 2026.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Allison Ambrose General Counsel Sale of securities on an exchange or to another person at price $ 9.29 per share. 16 Mar 2026 475 16,525 - 9.3 4,413 Common Stock
Adam Houghton Chief Business Officer Sale of securities on an exchange or to another person at price $ 9.29 per share. 16 Mar 2026 699 24,301 - 9.3 6,494 Common Stock
Aaron Deykin Chief Medical Officer Sale of securities on an exchange or to another person at price $ 9.29 per share. 16 Mar 2026 894 32,687 - 9.3 8,305 Common Stock
Everett Rand Sutherland Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 9.29 per share. 16 Mar 2026 2,093 72,907 - 9.3 19,444 Common Stock
Michael Paul Gray CFO and COO Sale of securities on an exchange or to another person at price $ 9.29 per share. 16 Mar 2026 852 29,648 - 9.3 7,915 Common Stock
Aaron Deykin Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2026 32,000 33,581 - 0 Common Stock
Michael Paul Gray CFO and COO Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2026 30,500 30,500 - 0 Common Stock
Michael Paul Gray CFO and COO Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2026 91,500 91,500 - - Stock Option (Right to Buy)
Everett Rand Sutherland Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2026 225,000 225,000 - - Stock Option (Right to Buy)
Everett Rand Sutherland Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2026 75,000 75,000 - 0 Common Stock
Aaron Deykin Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2026 96,000 96,000 - - Stock Option (Right to Buy)
Adam Houghton Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2026 75,000 75,000 - - Stock Option (Right to Buy)
Adam Houghton Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2026 25,000 25,000 - 0 Common Stock
Allison Ambrose General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2026 17,000 17,000 - 0 Common Stock
Allison Ambrose General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2026 51,000 51,000 - - Stock Option (Right to Buy)
Ronald C. Renaud Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Jun 2025 17,096 17,096 - - Stock Option (Right to Buy)
Marcella Kuhlman Ruddy Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Jun 2025 17,096 17,096 - - Stock Option (Right to Buy)
H. Edward Fleming Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Jun 2025 17,096 17,096 - - Stock Option (Right to Buy)
Erez Chimovits Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Jun 2025 17,096 17,096 - - Stock Option (Right to Buy)
Liam Ratcliffe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Jun 2025 17,096 17,096 - - Stock Option (Right to Buy)
Daniella Beckman Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Jun 2025 17,096 17,096 - - Stock Option (Right to Buy)
Allison Ambrose General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Feb 2025 25,000 25,000 - - Stock Option (Right to Buy)
Adam Houghton Chief Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Feb 2025 140,000 140,000 - - Stock Option (Right to Buy)
Aaron Deykin Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Feb 2025 165,000 165,000 - - Stock Option (Right to Buy)
Everett Rand Sutherland Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Feb 2025 500,000 500,000 - - Stock Option (Right to Buy)
Paul CFO and COO Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Feb 2025 195,000 195,000 - - Stock Option (Right to Buy)
Allison Ambrose General Counsel 16 Dec 2024 100,000 100,000 - - Stock Option (Right to Buy)
Chimovits Erez Director, Ten Percent Owner 15 Oct 2024 2,098,000 0 - - Series A redeemable convertible preferred stock
Erez Chimovits Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 17.00 per share. 15 Oct 2024 660,000 4,554,873 - 17 11,220,000 Common Stock
Chimovits Erez Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 17.00 per share. 15 Oct 2024 165,000 1,138,716 - 17 2,805,000 Common Stock
Chimovits Erez Director, Ten Percent Owner 15 Oct 2024 524,500 0 - - Series A redeemable convertible preferred stock
Erez Chimovits Director, Ten Percent Owner 15 Oct 2024 789,833 0 - - Series B redeemable convertible preferred stock
Erez Chimovits Director, Ten Percent Owner 15 Oct 2024 197,456 0 - - Series B redeemable convertible preferred stock
Chimovits Erez Director, Ten Percent Owner 15 Oct 2024 2,887,833 3,894,873 - - Common Stock
Erez Chimovits Director, Ten Percent Owner 15 Oct 2024 721,956 973,716 - - Common Stock
Fleming H. Edward Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Oct 2024 17,096 17,096 - - Stock Option (Right to Buy)
Daniella Beckman Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Oct 2024 34,681 34,681 - - Stock Option (Right to Buy)
Ratcliffe Liam Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Oct 2024 17,096 17,096 - - Stock Option (Right to Buy)
Erez Chimovits Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Oct 2024 17,096 17,096 - - Stock Option (Right to Buy)
Ruddy Marcella Kuhlman Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Oct 2024 17,096 17,096 - - Stock Option (Right to Buy)
Ronald C. Renaud Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Oct 2024 17,096 17,096 - - Stock Option (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters